PMD · Psychemedics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $12.58M | $13.69M | $15.95M | $14.64M | $16.47M | $21.23M |
| Gross Profit | $7.10M | $8.41M | $9.29M | $10.26M | $4.89M | $16.44M |
| R&D | $749.0K | $1.14M | $1.33M | $1.13M | $1.28M | $1.57M |
| SG&A | $5.70M | $7.19M | $5.86M | $6.13M | $6.09M | $7.22M |
| Total Operating Expenses | $8.99M | $11.33M | $10.37M | $10.05M | $10.95M | $13.45M |
| D&A | $1.10M | $1.70M | $2.40M | $2.70M | $2.60M | $2.91M |
| Operating Income | ($1.89M) | ($2.92M) | ($1.08M) | $209.0K | ($6.07M) | $3.00M |
| Interest Expense | $26.0K | $17.0K | $32.0K | $49.0K | $75.0K | $59.0K |
| Income Tax | ($55.0K) | $716.0K | $44.0K | ($156.0K) | ($2.35M) | $1.51M |
| Net Income | ($1.86M) | ($4.15M) | ($1.08M) | ($665.0K) | ($3.86M) | $1.54M |
| EPS - Basic | ($0.32) | ($0.72) | ($0.19) | ($0.12) | ($0.70) | $0.28 |
| EPS - Diluted | - | - | ($0.19) | ($0.12) | ($0.70) | $0.28 |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.42M | $1.96M | $4.75M | $1.99M | $2.83M | $3.94M |
| Accounts Receivable | $2.50M | $3.69M | $3.74M | $4.12M | $3.36M | $3.78M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $462.0K | $752.0K | $448.0K | $994.0K | $577.0K | $617.0K |
| Current Assets | $4.94M | $6.80M | $9.96M | $10.29M | $9.60M | $12.85M |
| Total Assets | $8.32M | $12.33M | $18.73M | $21.55M | $24.00M | $27.53M |
| Current Liabilities | $2.71M | $4.71M | $5.72M | $5.83M | $3.94M | $5.83M |
| Long-term Debt | - | $0 | $305.0K | $599.0K | $3.44M | $1.95M |
| Total Liabilities | $3.19M | $5.65M | $7.96M | $9.31M | $11.49M | $10.71M |
| Stockholders' Equity | $5.13M | $6.67M | $10.77M | $12.24M | $12.51M | $16.82M |
| Retained Earnings | ($18.63M) | ($16.77M) | ($11.82M) | ($9.55M) | ($8.61M) | ($3.75M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $929.0K | ($1.48M) | $4.89M | $414.0K | ($4.08M) | $4.31M |
| Investing Cash Flow | ($87.0K) | ($159.0K) | ($208.0K) | ($220.0K) | ($858.0K) | $2.08M |
| Financing Cash Flow | ($1.39M) | ($1.15M) | ($1.92M) | ($1.03M) | $501.0K | ($3.00M) |
| CapEx | $51.0K | $157.0K | $187.0K | $182.0K | $991.0K | $1.68M |
| Free Cash Flow | $878.0K | ($1.64M) | $4.70M | $232.0K | ($5.07M) | $2.63M |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | -0.47 | 0.39 | -4.34 | -0.35 | 1.31 | 1.71 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | 49.5% |
| Return on assets | -22.4% | -33.7% | -5.8% | -3.1% | -16.1% | 5.6% |
| Return on equity | -36.3% | -62.3% | -10.1% | -5.4% | -30.8% | 9.2% |
| Return on invested capital | - | -34.6% | -7.7% | 1.3% | -30.0% | 8.1% |
| Liquidity | ||||||
| Current ratio | 1.82 | 1.45 | 1.74 | 1.76 | 2.44 | 2.20 |
| Quick ratio | 1.82 | 1.45 | 1.74 | 1.76 | 2.44 | 2.20 |
| Cash ratio | 0.52 | 0.42 | 0.83 | 0.34 | 0.72 | 0.67 |
| Leverage | ||||||
| Debt / Equity | - | 0.00 | 0.03 | 0.05 | 0.28 | 0.12 |
| Debt / Assets | - | 0.00 | 0.02 | 0.03 | 0.14 | 0.07 |
| Debt / EBITDA | - | - | 0.23 | 0.21 | - | 0.33 |
| Interest coverage | -72.8x | -171.8x | -33.8x | 4.3x | -80.9x | 50.8x |
| Equity multiplier | 1.62 | 1.85 | 1.74 | 1.76 | 1.92 | 1.64 |
| Liabilities / Assets | 0.38 | 0.46 | 0.42 | 0.43 | 0.48 | 0.39 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 13d | 20d | 10d | 25d | 13d | 11d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -15.6% | -9.5% | -9.5% | 110.1% | -70.3% | -20.2% |
| Operating income growth (YoY) | 35.2% | -169.7% | - | - | - | -60.6% |
| Net income growth (YoY) | 55.2% | -283.2% | -63.0% | 82.8% | - | -66.4% |
| EPS growth (YoY) | - | - | -58.3% | 82.9% | - | -66.3% |
| EPS CAGR (3y) | - | - | - | - | - | -38.8% |
| EPS CAGR (5y) | - | - | - | - | - | -14.1% |
| FCF growth (YoY) | - | - | 1927.2% | - | - | -60.9% |
| FCF CAGR (5y) | -19.7% | - | -10.2% | -49.8% | - | - |
| Book value growth (YoY) | -23.1% | -38.1% | -12.0% | -2.1% | -25.6% | -10.3% |
Stability scores
Piotroski F-score
FY 2024 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing PSYCHEMEDICS CORP against the 5 most active filers in the same SIC group.